These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 34306793)

  • 1. Nivolumab and Ipilimumab Combination Immunotherapy for Patients with Metastatic Collecting Duct Carcinoma.
    Danno T; Iwata S; Niimi F; Honda S; Okada H; Azuma T
    Case Rep Urol; 2021; 2021():9936330. PubMed ID: 34306793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complete response to combination therapy using nivolumab and ipilimumab for metastatic, sarcomatoid collecting duct carcinoma presenting with high expression of programmed death-ligand 1: a case report.
    Fuu T; Iijima K; Kusama Y; Otsuki T; Kato H
    J Med Case Rep; 2022 May; 16(1):193. PubMed ID: 35581611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complete response to combination therapy with nivolumab and ipilimumab for metastatic collecting duct carcinoma of the kidney.
    Watanabe K; Sugiyama T; Otsuka A; Miyake H
    Int Cancer Conf J; 2020 Jan; 9(1):32-35. PubMed ID: 31950015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frontline immunotherapy treatment with nivolumab and ipilimumab in metastatic renal cell cancer: a new standard of care.
    Nizam A; Aragon-Ching JB
    Cancer Biol Ther; 2019; 20(1):6-7. PubMed ID: 30332546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone.
    Afzal MZ; Mabaera R; Shirai K
    J Immunother Cancer; 2018 Feb; 6(1):13. PubMed ID: 29433557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response to nivolumab in metastatic collecting duct carcinoma expressing PD-L1: A case report.
    Mizutani K; Horie K; Nagai S; Tsuchiya T; Saigo C; Kobayashi K; Miyazaki T; Deguchi T
    Mol Clin Oncol; 2017 Dec; 7(6):988-990. PubMed ID: 29285361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
    Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
    Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Persistent Response to a Combination Treatment Featuring a Targeted Agent and an Immune Checkpoint Inhibitor in a Patient With Collecting Duct Renal Carcinoma: A Case Report and Literature Review.
    Zhou W; Huang J; He Q; Luo Q; Zhang X; Tao X; Dong H; Tu X
    Front Oncol; 2021; 11():764352. PubMed ID: 34820330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Safety and Efficacy of Checkpoint Inhibitors in Transplant Recipients: A Case Series and Systematic Review of Literature.
    Kumar V; Shinagare AB; Rennke HG; Ghai S; Lorch JH; Ott PA; Rahma OE
    Oncologist; 2020 Jun; 25(6):505-514. PubMed ID: 32043699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increase in Efficacy of Checkpoint Inhibition by Cytokine-Induced-Killer Cells as a Combination Immunotherapy for Renal Cancer.
    Dehno MN; Li Y; Weiher H; Schmidt-Wolf IGH
    Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32349280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Rare Case of Immune-Mediated Primary Adrenal Insufficiency With Cytotoxic T-Lymphocyte Antigen-4 Inhibitor Ipilimumab in Metastatic Melanoma of Lung and Neck of Unknown Primary.
    Gaballa S; Hlaing KM; Mahler N; Moursy S; Ahmed A
    Cureus; 2020 Jun; 12(6):e8602. PubMed ID: 32676241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of Bell's Palsy After Treatment With Ipilimumab and Nivolumab for Metastatic Melanoma: A Case Report.
    Zecchini JM; Kim S; Yum K; Friedlander P
    J Immunother; 2018 Jan; 41(1):39-41. PubMed ID: 28926356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination therapy with PD-1 or PD-L1 inhibitors for cancer.
    Hayashi H; Nakagawa K
    Int J Clin Oncol; 2020 May; 25(5):818-830. PubMed ID: 31549270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metastatic renal cell carcinoma regains sensitivity to tyrosine kinase inhibitor after nivolumab treatment: A case report.
    Azuma T; Sugihara T; Honda S; Yoshizaki U; Niimi F; Tsuru I; Kume H
    Oncol Lett; 2019 Apr; 17(4):4011-4015. PubMed ID: 30881514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer?
    Tanvetyanon T; Gray JE; Antonia SJ
    Expert Opin Biol Ther; 2017 Mar; 17(3):305-312. PubMed ID: 28064556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BIONIKK: A phase 2 biomarker driven trial with nivolumab and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in naïve metastatic kidney cancer.
    Epaillard N; Simonaggio A; Elaidi R; Azzouz F; Braychenko E; Thibault C; Sun CM; Moreira M; Oudard S; Vano YA
    Bull Cancer; 2020 Jun; 107(5S):eS22-eS27. PubMed ID: 32620212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thrombotic Thrombocytopenic Purpura due to Checkpoint Inhibitors.
    Youssef A; Kasso N; Torloni AS; Stanek M; Dragovich T; Gimbel M; Mahmoud F
    Case Rep Hematol; 2018; 2018():2464619. PubMed ID: 30671268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma: A systematic review and meta-analysis of randomized controlled trials.
    Hao C; Tian J; Liu H; Li F; Niu H; Zhu B
    Medicine (Baltimore); 2017 Jun; 96(26):e7325. PubMed ID: 28658143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response to combined ipilimumab and nivolumab after development of a nephrotic syndrome related to PD-1 monotherapy.
    Glutsch V; Grän F; Weber J; Gesierich A; Goebeler M; Schilling B
    J Immunother Cancer; 2019 Jul; 7(1):181. PubMed ID: 31300044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.